BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29097363)

  • 1. Interrogation of the Atherosclerosis-Associated
    Wang X; Raghavan A; Peters DT; Pashos EE; Rader DJ; Musunuru K
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):76-82. PubMed ID: 29097363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus.
    Musunuru K; Strong A; Frank-Kamenetsky M; Lee NE; Ahfeldt T; Sachs KV; Li X; Li H; Kuperwasser N; Ruda VM; Pirruccello JP; Muchmore B; Prokunina-Olsson L; Hall JL; Schadt EE; Morales CR; Lund-Katz S; Phillips MC; Wong J; Cantley W; Racie T; Ejebe KG; Orho-Melander M; Melander O; Koteliansky V; Fitzgerald K; Krauss RM; Cowan CA; Kathiresan S; Rader DJ
    Nature; 2010 Aug; 466(7307):714-9. PubMed ID: 20686566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy Is Required for Sortilin-Mediated Degradation of Apolipoprotein B100.
    Amengual J; Guo L; Strong A; Madrigal-Matute J; Wang H; Kaushik S; Brodsky JL; Rader DJ; Cuervo AM; Fisher EA
    Circ Res; 2018 Feb; 122(4):568-582. PubMed ID: 29301854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage sortilin promotes LDL uptake, foam cell formation, and atherosclerosis.
    Patel KM; Strong A; Tohyama J; Jin X; Morales CR; Billheimer J; Millar J; Kruth H; Rader DJ
    Circ Res; 2015 Feb; 116(5):789-96. PubMed ID: 25593281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced Pluripotent Stem Cell Differentiation Enables Functional Validation of GWAS Variants in Metabolic Disease.
    Warren CR; O'Sullivan JF; Friesen M; Becker CE; Zhang X; Liu P; Wakabayashi Y; Morningstar JE; Shi X; Choi J; Xia F; Peters DT; Florido MHC; Tsankov AM; Duberow E; Comisar L; Shay J; Jiang X; Meissner A; Musunuru K; Kathiresan S; Daheron L; Zhu J; Gerszten RE; Deo RC; Vasan RS; O'Donnell CJ; Cowan CA
    Cell Stem Cell; 2017 Apr; 20(4):547-557.e7. PubMed ID: 28388431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Trait Locus Mapping of Macrophage Cholesterol Metabolism and CRISPR/Cas9 Editing Implicate an ACAT1 Truncation as a Causal Modifier Variant.
    Hai Q; Ritchey B; Robinet P; Alzayed AM; Brubaker G; Zhang J; Smith JD
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):83-91. PubMed ID: 29097366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Missense variants in SORT1 are associated with LDL-C in an Amish population.
    Mitok KA; Schueler KL; King SM; Orr J; Ryan KA; Keller MP; Krauss RM; Mitchell BD; Shuldiner AR; Attie AD
    J Lipid Res; 2023 Dec; 64(12):100468. PubMed ID: 37913995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice.
    Chen C; Li J; Matye DJ; Wang Y; Li T
    J Lipid Res; 2019 Mar; 60(3):539-549. PubMed ID: 30670473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
    VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
    Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proof-of-Concept Gene Editing for the Murine Model of Inducible Arginase-1 Deficiency.
    Sin YY; Price PR; Ballantyne LL; Funk CD
    Sci Rep; 2017 May; 7(1):2585. PubMed ID: 28566761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology.
    Estève J; Blouin JM; Lalanne M; Azzi-Martin L; Dubus P; Bidet A; Harambat J; Llanas B; Moranvillier I; Bedel A; Moreau-Gaudry F; Richard E
    Biochem Biophys Res Commun; 2019 Oct; 517(4):677-683. PubMed ID: 31402115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
    Wang X; Raghavan A; Chen T; Qiao L; Zhang Y; Ding Q; Musunuru K
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):783-6. PubMed ID: 26941020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Thrombotic Function of a Human SNP in STXBP5 Revealed by CRISPR/Cas9 Gene Editing in Mice.
    Zhu QM; Ko KA; Ture S; Mastrangelo MA; Chen MH; Johnson AD; O'Donnell CJ; Morrell CN; Miano JM; Lowenstein CJ
    Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):264-270. PubMed ID: 28062498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice.
    Ai D; Baez JM; Jiang H; Conlon DM; Hernandez-Ono A; Frank-Kamenetsky M; Milstein S; Fitzgerald K; Murphy AJ; Woo CW; Strong A; Ginsberg HN; Tabas I; Rader DJ; Tall AR
    J Clin Invest; 2012 May; 122(5):1677-87. PubMed ID: 22466652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia.
    Zhao H; Li Y; He L; Pu W; Yu W; Li Y; Wu YT; Xu C; Wei Y; Ding Q; Song BL; Huang H; Zhou B
    Circulation; 2020 Jan; 141(1):67-79. PubMed ID: 31779484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sortilin and lipoprotein metabolism: making sense out of complexity.
    Strong A; Patel K; Rader DJ
    Curr Opin Lipidol; 2014 Oct; 25(5):350-7. PubMed ID: 25101658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing.
    Chadwick AC; Wang X; Musunuru K
    Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1741-1747. PubMed ID: 28751571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
    Zhang Y; Sastre D; Wang F
    Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.